BONK, INC. quarterly report, Q1 FY2021

Filing identity and reporting period

The supplied filing is Jupiter Wellness, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021, filed May 17, 2021. This does not match the request metadata identifying BONK, INC.; verify the issuer before relying on this summary.

Jupiter Wellness describes itself as an early-stage developer and marketer of cannabidiol (CBD) wellness and therapeutic products. Its consolidated subsidiaries include Magical Beasts and SRM Entertainment.

Financial results and liquidity

At March 31, 2021, cash was $3.01 million, total assets $5.08 million, total liabilities $650,755, and shareholders’ equity $4.43 million. Current assets were $3.59 million against current liabilities of $650,755. The balance sheet showed an $84,578 COVID-19 SBA loan; convertible notes and the acquisition note were no longer outstanding at quarter-end. Lease liabilities totaled $24,606.

Operating expenses were substantially affected by stock-based compensation: the cash flow statement reports $1.67 million, and the MD&A reports $1.68 million. The company recorded $60,529 of research and development expense. The quarter’s $669,200 of other income was a gain related to the Magical Beasts settlement.

Changes from the prior comparable period

• Revenue declined about 58% year over year. Management attributed weaker demand for traditional products to the COVID-19 pandemic.
• Gross profit increased despite lower sales, and gross margin rose to 52.0% from 15.1%, reflecting lower cost of sales.
• Net loss increased to $2.20 million from $481,798. General and administrative expense and share-based compensation rose sharply.
• Operating cash use increased to $1.25 million from $457,638. Cash fell by $1.25 million from year-end 2020.
• Common shares outstanding rose from 10,655,833 at December 31, 2020 to 11,260,188 at March 31, 2021, including shares issued on note conversion, option exercises, and compensation.

Outlook, risks, contingencies, and unusual items

• Going concern: Management states that recurring losses, operating cash use, and continuing development costs raise substantial doubt about the company’s ability to continue as a going concern. Its plans include cost control, limiting cash commitments, seeking equity financing, and potentially deferring research and clinical-trial work. Failure to obtain sufficient revenue or financing could require curtailing operations or pursuing arrangements that dilute existing shareholders.
• Product development: The company reported results from a small JW-100 eczema study: 50% of participants in the CBD-and-aspartame arm achieved the stated clear/almost-clear outcome with at least a two-grade improvement, versus 20% for CBD alone and 15% for placebo; the filing reports p=0.028. Further development and FDA-regulated studies are not assured. Management said development studies had been delayed by COVID-19.
• Subsequent financing: On May 11, 2021, the company entered a $2.5 million convertible note agreement, due November 10, 2021, with an 8% interest rate, 5% original issue discount, and $6 conversion price (adjustable to $5 on default). The financing also includes warrants for 416,667 shares and down-round protection. This transaction occurred after quarter-end.
• Settlement and litigation: An amendment to the Magical Beasts arrangements forgave the remaining acquisition note and led to the $669,200 gain; it also relinquished the company’s rights to the Bella brand and revised the former owner’s option and employment arrangements. A separate lawsuit’s claims were dismissed on April 24, 2021. The company sought $5 million in actual and $5 million in punitive damages; the filing does not report a recovery.
• Controls: The filing contains inconsistent statements: one passage describes disclosure controls as effective, while the quarter-end assessment concludes they were ineffective, citing reliance on a small team. Management said it plans to expand the team and develop a fuller internal-control framework.
• Guidance: The filing provides no quantified financial guidance or forecast.

Important facts for investors to verify

• Confirm that Jupiter Wellness, rather than BONK, INC., is the intended filing and issuer.
• Review the going-concern disclosure, expected cash requirements, and whether subsequent financing is sufficient relative to operating cash burn.
• Assess the terms, maturity, conversion and warrant dilution, and down-round protections of the May 2021 financing.
• Reconcile the filing’s inconsistent disclosure-controls conclusions and the differing stock-compensation figures reported in the cash flow statement and MD&A.
• Evaluate the limited revenue base and the clinical, regulatory, commercialization, and COVID-related risks affecting product development and demand.